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DNA methylation is a central epigenetic modifi-
cation that is established by de novo DNA methyl-
transferases. The mechanisms underlying the gene-
ration of genomic methylation patterns are still
poorly understood. Using mass spectrometry and
a phosphospecific Dnmt3a antibody, we demon-
strate that CK2 phosphorylates endogenous Dnmt3a
at two key residues located near its PWWP domain,
thereby downregulating the ability of Dnmt3a to
methylate DNA. Genome-wide DNA methylation
analysis shows that CK2 primarily modulates CpG
methylation of several repeats, most notably of
Alu SINEs. This modulation can be directly attributed
to CK2-mediated phosphorylation of Dnmt3a. We
also find that CK2-mediated phosphorylation is
required for localization of Dnmt3a to heterochro-
matin. By revealing phosphorylation as a mode
of regulation of de novo DNA methyltransferase
function and by uncovering a mechanism for the
regulation of methylation at repetitive elements, our
results shed light on the origin of DNA methylation
patterns.INTRODUCTION
DNA methylation in mammalian somatic cells is mainly confined
to cytosine bases within CpG dinucleotides. It is associated with
a repressed chromatin state and inhibition of gene expression
(Deaton and Bird, 2011). Methylated CpG dinucleotides are not
randomly distributed throughout the genome. Rather, some
genomic sequences (e.g., heterochromatic DNA) are heavily
methylated, while others, such as CpG islands in the promoter
regions of many genes, are usually methylation-free (Deaton
and Bird, 2011). The establishment of DNA methylation patterns
inmammalian cells resultsmainly from the action of the so-called
de novo DNA methyltransferases Dnmt3a and Dnmt3b (Denis
et al., 2011; Law and Jacobsen, 2010; Okano et al., 1999). Apart
from some sequence specificity for residues flanking the CpG
site (e.g., Handa and Jeltsch, 2005; Jurkowska et al., 2011; Lin
et al., 2002), these enzymes do not appear to have any sequence
specificity, so themechanisms underlying the generation of DNA
methylation patterns by Dnmts remain poorly understood.
Because phosphorylation is a very important posttranslational
modification that can control protein-protein interactions, enzy-
matic activities, and subcellular localization of proteins and has
a role in many cellular processes (Johnson and Barford, 1993),
we examined whether phosphorylation might regulate the func-
tion of the Dnmt3a de novo DNA methyltransferase. We focused
on Dnmt3a because not much is known about PTMmodificationCell Reports 8, 743–753, August 7, 2014 ª2014 The Authors 743
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Figure 1. The De Novo DNAMethyltransfer-
ase Dnmt3a Is Phosphorylated by CK2
In Vitro and In Vivo
(A) Orthophosphate labeling of Dnmt3a-over-
expressing cells. U2OS cells were transiently
transfected with Myc-Dnmt3a (lane 2) or empty
vector (lane 1) and incubated with 32Pi for 4 hr prior
to immunoprecipitation (IP) with Myc antibody. A
representative experiment is shown, which was
successfully repeated three times.
(B) Orthophosphate labeling of untransfected
cells, followed by mock IP (lane 1) or IP with anti-
Dnmt3a (lane 2). A representative experiment is
shown, which was successfully repeated twice.
(C) Pharmacological inhibition of various kinases
suggests that CK2 plays a major role in Dnmt3a
phosphorylation. U2OS cells were transiently
transfected with Myc-Dnmt3a or empty vector
prior to IP with anti-Myc. Immunoprecipitated
extracts were supplemented with g32P-[ATP] in
the presence or absence of the indicated kinase
inhibitors. Loading controls are shown in the lower
panel. A representative experiment is shown,
which was repeated three times.
(D) The kinase that phosphorylates Dnmt3a dis-
plays a unique feature of CK2: it can use GTP as
well as ATP. Experiments were performed as in
(C), with either g32P-ATP (lanes 1 and 2) or g32P-
[GTP] (lanes 3 and 4). Apigenin inhibitor was used
as indicated. A representative experiment is
shown, which was repeated twice.
(E) CK2 phosphorylates bacterially expressed
Dnmt3a. In vitro kinase assays were performed
with His-Dnmt3a and recombinant CK2. Recom-
binant PKA was used as negative control. A
representative experiment is depicted, which was
repeated three times. In each panel, the vertical
line indicates juxtaposition of lanes nonadjacent
within the same blot/film, exposed for the same
time.of this particular Dnmt, yet there is a growing interest in better
understanding its function in physiological and pathological con-
texts. For example, Dnmt3a has now been shown to be mutated
in several cancers (Roller et al., 2013).
RESULTS
The De Novo DNA Methyltransferase Dnmt3a Is
Phosphorylated by CK2 In Vitro and In Vivo
To investigate whether Dnmt3a undergoes phosphorylation, we
first performed in vivo 32P-orthophosphate labeling experiments
after transfection of U2OS human osteosarcoma cells with a
construct encoding Myc-tagged mouse Dnmt3a. After immuno-
precipitation of Myc-Dnmt3a with anti-Myc and subsequent
SDS-PAGE, we observed a band of overexpressed Dnmt3a hav-
ing incorporated 32P, whereas mock-transfected cells showed744 Cell Reports 8, 743–753, August 7, 2014 ª2014 The Authorsno corresponding band (Figure 1A).
Similar experiments with 32P-labeled
nontransfected U2OS cells revealed, af-
ter immunoprecipitation of endogenousDnmt3a, that this human enzyme was also phosphorylated (Fig-
ure 1B, lane 2). As a negative control, a mock immunoprecipita-
tion was carried out with the same labeled extracts (Figure 1B,
lane 1). Dnmt3a is thus posttranslationally modified by phos-
phorylation in vivo.
Next, to identify the kinase(s) responsible for the observed
Dnmt3a phosphorylation, we purified Myc-tagged Dnmt3a
from U2OS cells by immunoprecipitation and subjected it to in
vitro kinase assays performed with cell extracts supplemented
or not with various kinase inhibitors. In agreement with the
data presented in Figures 1A and 1B, this assay revealed the
presence of phosphorylated Dnmt3a (Figure 1C, lane 1). Dnmt3a
phosphorylation was unaffected by several kinase inhibitors,
such as H89 and staurosporine (Figure 1C, lanes 3 and 5), known
to primarily inhibit protein kinase A (PKA) and protein kinase
C (PKC), respectively. In contrast, two potent inhibitors of CK2
activity, apigenin and Drb, caused a robust decrease in Dnmt3a
phosphorylation (Figure 1C, lanes 2 and 4). Dnmt3a protein
levels were unaffected by inhibitor treatment (Figure 1C, lower
panel). This suggests that the ubiquitous serine/threonine pro-
tein kinase CK2 (St-Denis and Litchfield, 2009) plays a major
role in Dnmt3a phosphorylation.
As kinase inhibitors often affect the activity of more than one
kinase, we performed additional sets of experiments to further
test this conclusion. First, we exploited a feature unique to
CK2 among kinases: its ability to use GTP as well as ATP as a
phosphate source (Mazzorana et al., 2008). In vitro kinase as-
says similar to those shown in Figure 1C revealed phosphoryla-
tion of Dnmt3a in the presence of g-[32P] GTP, albeit to a lower
level than when labeled ATP was used (Figure 1D). Second, to
test directly whether Dnmt3a can be a substrate of CK2, we per-
formed an in vitro kinase reaction using bacterially expressed
histidine-tagged Dnmt3a and recombinant CK2 in the presence
of labeled ATP. After SDS-PAGE and autoradiography, Dnmt3a
appeared to be efficiently phosphorylated by CK2 (Figure 1E,
lane 2). In a negative control where recombinant PKA was
included instead of CK2 (Figure 1E, lane 3), Dnmt3a remained
unlabeled.
Dnmt3a Is Phosphorylated by CK2 at S386 and S389
Having established Dnmt3a is a bona fide substrate for CK2, we
set out to identify the target residues of CK2. In silico screening
for CK2 consensus sites S/TxxD/E or S/TxD/E (Allende and Al-
lende, 1995) revealed several potential sites in two regions of
Dnmt3a, one encompassing its conserved Pro-Trp-Trp-Pro
motif (PWWP) domain (also called the ‘‘extended PWWP’’ below)
and one comprising its C-terminal catalytic domain. In vitro ki-
nase assays using recombinant CK2 revealed efficient phos-
phorylation of a Dnmt3a fragment spanning residues 279–420,
overlapping with the PWWP domain (Figure 2A, lane 3). In
contrast, the catalytic and ATRX-Dnmt3-Dnmt3L (ADD) domains
of Dnmt3a (Figure 2A, lanes 2 and 7, respectively) were not
appreciably phosphorylated. The extended PWWP region con-
tains two potential CK2 sites, at serines 386 and 389, which
are conserved among all Dnmt3a homologs (Figure 2C and Fig-
ure S1C). A CK2 kinase assay using variants where S386, S389,
or both were replaced with A (so that these sites could no
longer be phosphorylated) showed that each single mutation
decreased phosphorylation weakly and the presence of both
mutations almost completely abolished phosphorylation (Fig-
ure 2A, lanes 4, 5, and 6). Consistently with the above data,
replacement of residues S386 and S389 with E (mimicking the
phosphorylated state) abolished phosphorylation by CK2 (Fig-
ure 2B, lane 4). (One should note that the higher phosphorylation
observed with the S389E single mutant [Figure 2B, lane 3] may
be related to the fact that the peptidemotif more closelymatches
the CK2 consensus target motif after the serine-to-glutamic acid
mutation.) To provide additional evidence, mass spectrometry
analysis was also performed with the purified extended PWWP
domain after the in vitro CK2 kinase assay, gel purification, and
chyomotryptic digestion. As shown in Figure 2D (and Figures
S1A and S1B), a peptide containing both serine residues in phos-
phorylated form was identified. The structure of the Dnmt3a
PWWP domain shows that the loop containing both serine resi-dues is not ordered but exposed at the surface of the domain,
indicating that it is accessible to CK2 (Figure S1C, lower part).
Next, with an antibody raised against S390- and/or S393-
phosphorylated human Dnmt3a (these residues correspond
to mouse residues S386 and S389; cf. Figure 2C), we demon-
strated that endogenous Dnmt3a is phosphorylated by CK2
in vivo. As shown in Figure 2E, the antibody recognized a single
band (lane 1), which was abolished in the presence of the singly
or doubly phosphorylated peptide used for immunization (lanes
2–4), but not in the presence of its unphosphorylated equivalent
(lane 5).
Lastly, to obtain further in vivo data on CK2-mediated
Dnmt3a phosphorylation, we used RNAi to knock down CK2a
in U2OS cells (Figure S2). By western blotting with the antibody
against phospho-Dnmt3a, we observed a strong reduction of
Dnmt3a phosphorylation in U2OS cells depleted of CK2
(Figure 2F).
Altogether, these data identify two serines of Dnmt3a as
targets of CK2-mediated phosphorylation.
CK2 Negatively Regulates the Ability of Dnmt3a to
Methylate DNA and Decreases the Overall Genomic
Level of 5-Methylcytosine
We next evaluated the functional consequences of CK2-medi-
ated Dnmt3a phosphorylation. Since the primary function of
mammalian Dnmt3a is to methylate DNA, we investigated
whether phosphorylation of Dnmt3a by CK2 might influence its
DNA methyltransferase activity. For this we initially used DNA
methyltransferase assays measuring the transfer of tritiated
methyl groups from S-adenosyl-L-[methyl-3H]methionine to a
synthetic oligonucleotide substrate (Jurkowska et al., 2008). A
recombinant Dnmt3a2/Dnmt3L complex was used to get higher
enzyme activity (Dnmt3L was not phosphorylated by CK2; data
not shown); Dnmt3a2 is a catalytically active Dnmt3a isoform
(Chen et al., 2002). As depicted in Figure 3A, using DNA methyl-
transferase (DNMT) assays with recombinant Dnmt3, we found
the DNA methyltransferase activity of the Dnmt3a2/Dnmt3L
complex to be significantly reduced in the presence of recombi-
nant CK2. Similar results were obtained in DNMT assays with
lysate from transfected cells (Figure 3B). In these experiments,
Dnmt3a was overexpressed in U2OS cells with or without CK2
wild-type (WT) or a catalytically inactive mutant (Penner et al.,
1997). As shown in Figure 3B, Dnmt3a overexpression in U2OS
cells led to increased DNMT activity as compared to mock-
transfected cells (lanes 1 and 2). When exogenous Dnmt3a
was produced together with CK2, the DNMT activity was
reduced to the level detected in mock-transfected cells (Fig-
ure 3B, lanes 1 and 4). No such effect was observed when
Dnmt3a was overexpressed together with the the catalytically
inactive CK2 mutant or with PKA (Figure 3B, lanes 5 and 6).
We also performed DNMT assays using phosphomimetic
Dnmt3amutants. As shown in Figure 3C, DNAmethyltransferase
activity was slightly lower with either single phosphomimetic
mutant (S386E or S389E) than with the wild-type, and the
S386E/S389E double mutant showed even lower DNMT activity.
Additional controls showed that inactivated CK2 did not repress
Dnmt3a and Dnmt3a mutants were not affected by CK2 either
(Figure S3).Cell Reports 8, 743–753, August 7, 2014 ª2014 The Authors 745
Dnmt3a
8091 PWWP CAT
286 372 630
ADD
490 582
Dnmt3a2 WT
 S386E
S386E
S389E
 S389E
S389ES386E S386E
+S389E
S389AS386A
 S386A
+S389A
B
Coomassie staining
*
*
* * * *
*
1 2 3 4 5 6 7
PWWP
Dnmt3a
8091 PWWP CAT
286 372 630
ADD
490 582
senaL
A
In vitro kinase assay
1 2 3 4 5 6 7
*
* *
*
* *
*
In vitro kinase assay
Coomassie staining
* * * * *
1 2 3 4 5
1 2 3 4 5
* * * * *
Dnmt3a2 WT 1
 Catalytic domain 2
 WT
279 420
3
 S386A
S386A
4
S389A
S389A
5
S386A S389AS386A
+S389A
6
ADD 7
1
2
3
4
5
C Dnmt3a
1 908PWWP CAT
286 372
ADD
490 582 630 D
Dnmt3a PWWP
Dnmt3a PWWP + CK2
0
100
200
300
400
2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080
Mass (m/z)
In
te
ns
 [a
.u
.]
20
52
.9
67
FPACHDSDESDSGKAVEV
E
Peptide 
competition:
WB:
S
38
6
S
38
9
SFPVCHDSDESDKLM. musculus:
KI FPACPENDETDT
KTFL SCPASDDTDS
KL FPACHDSDESDT
KL FPVCHDSDESDT
KL FPACHDSDESDT
KL FPMCHDSDESDT
R. norvegicus:
P. troglodyte:
C. lupus:
B. taurus:
G.gallus:
D. rerio:
KL FPACHDSDESDTH. sapiens:
S
39
0
S
39
3
hS390
hS393
p
un
-p
1 2 3 4 5
-
-
Phospho
-Dnmt3a
124kDa
phospho-Dnmt3a
p
p p
un
-p
un
-p
un
-p
F
WB: Phospho-Dnmt3a
WB: Actin
21
R
N
A
i
co
nt
ro
l
R
N
A
i
C
K
2α
Phospho
-Dnmt3a
senaL
Figure 2. Dnmt3a Is Phosphorylated by CK2
at S386 and S389
(A and B) His fusions of Dnmt3a2. The indicated
fusions were tested in in vitro kinase assays with
recombinant CK2. The middle panel shows auto-
radiograms of in vitro kinase assays performed
with the indicated His-Dnmt3a fusion proteins.
The lower panel shows Coomassie staining as
loading control. In each panel, a representative
experiment is shown, which was repeated three
times.
(C) Residues S386 and S389 (red), phosphorylated
in mouse Dnmt3a, are conserved among its
homologs from all species (e.g., S390/S393 in
humans).
(D) Mass spectrometry analysis of Dnmt3a after
phosphorylation by CK2. At a sequence coverage
of 72.4% and an intensity coverage of 38.2%, one
peptide is detected (2,052.96 Da; arrow), corre-
sponding to a doubly phosphorylated fragment
(FPACHDSDESDSGKAVEV, theoretical mass:
2,052.73 Da) containing S386 and S389 (in red,
underlined). This peak was not detected without
prior phosphorylation (in green). Numbers repre-
sent the masses of the substrate and product
peptides. The MALDI experiments were carried
out twice.
(E) Phosphorylation of endogenous human
Dnmt3a by CK2 in vivo. Lysates from un-
transfected U2OS cells were subjected to western
blotting with phospho (S390/393) human Dnmt3a
antibody in the absence and presence of the
indicated phosphorylated (p) or unphosphorylated
(un-p) peptide. A representative experiment is
shown, which was successfully repeated three
times. The vertical line indicates juxtaposition of
lanes within the same blot, exposed for the same
time.
(F) Human Dnmt3a phosphorylation is decreased
in CK2a-depleted U2OS cells. The western blot
with phospho (S390/393) human Dnmt3a antibody
shows reduction of endogenous DNMT3A phos-
phorylation in the presence of an RNAi targeting
CK2a (lane 2), as compared to an RNAi control
(lane 1). Actin levels were checked to confirm that
equal amounts of extract were used.Having established that CK2-mediated phosphorylation of
Dnmt3a reduces its DNA methyltransferase activity in vitro, we
examined the effect of CK2 on global DNA methylation in vivo.
To this end, we used a previously characterized inducible Tet-
Off U2OS cell line, where the levels of CK2a catalytic subunits
can be manipulated with tetracycline (Tc) (Vilk et al., 1999). In
the Tet-Off cell line, CK2a expression is at the endogenous level
in the absence of tetracycline but CK2a is strongly induced in the
presence of tetracycline (Vilk et al., 1999) (data not shown). In this
cell line, we measured the total 5-methylcytosine (5mC) content
by high-performance capillary electrophoresis (HPCE) (Fraga
et al., 2005). As shown in Figure 3D (lanes 1 and 2), increased
expression of CK2aWT (in the absence of Tc) resulted in a signif-
icantly decreased genomic 5mC content. As controls, we also
used a similar U2OS Tet-Off cell line, this time stably expressing746 Cell Reports 8, 743–753, August 7, 2014 ª2014 The Authorsa catalytically inactive CK2a. As depicted in Figure 3D (compare
lanes 3 and 4), induced expression of catalytically inactive CK2a
did not decrease the genomic 5mC content.
Next, we have performed HPCE experiments in U2OS
WT cells or cells depleted of CK2. As depicted in Figure 3E,
we found that an RNAi targeting CK2 led to a significant
increase in total CpG methylation (Figure 3E). These data,
obtained by manipulating endogenous CK2, further extend
and confirm the impact of CK2 on the overall genomic level
of 5-methylcytosine.
CK2 Influences Genome-wide CpG Methylation
To investigate the influence of CK2 on genome-wide DNA
methylation, we used the methylated DNA capture-sequencing
(MethylCap-seq) method, in which methylated genomic DNA is
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Figure 3. CK2 Negatively Regulates the
Ability of Dnmt3a to Methylate DNA and De-
creases the Overall Genomic Level of 5-
Methylcytosine
(A) CK2 reduces Dnmt3a methyltransferase ac-
tivity. Following phosphorylation of Dnmt3a2 by
CK2 as indicated, DNA methyltransferase activity
was assayed by incubating an oligonucleotide
substrate with S-adenosyl-L-[methyl-3H]-methio-
nine and measuring incorporation of the radio-
labeled methyl group into the substrate. The re-
combinant Dnmt3a2+Dnmt3L complex was used
to get higher enzyme activity. Error bars represent
SD of biological duplicates.
(B) CK2 reduces DNMT activity in transfected
cells. U2OS cells were transfected so as to ex-
press Dnmt3a and/or CK2 WT or a catalytically
inactive mutant (Penner et al., 1997) thereof.
In vitro kinase assays followed by DNMT assays
were then performed. PKA, used as a negative
control, did not alter DNMT activity. Error bars
represent SD of biological duplicates.
(C) Use of a phosphomimetic Dnmt3a mutant re-
sults in decreased DNMT activity. Experiments
were done as in (A) with the indicated recombinant
Dnmt3a2 protein. Error bars represent SD of bio-
logical duplicates.
(D) CK2 decreases overall genomic DNA methyl-
ation. HPCE (Fraga et al., 2005) was performed on
extracts of Tet-Off CK2 cells to measure the total
5mC content. Error bars represent SD of duplicate
experiments.
(E) CK2-depleted cells show an increased global
DNA methylation level. Total genomic 5mC was
measured byHPCE onDNA fromRNAi control and
CK2 RNAi U2Os cells. Error bars represent SD of
triplicate experiments.captured by affinity purification with a methyl-binding domain
(MBD) protein and subjected to high-throughput sequencing
(Bock et al., 2010; Martens et al., 2010). First, we focused on
the nonrepetitive portion of the genome. As shown in Figure 4A,
CK2-depleted cells and control cells showed the same Methyl-
Cap-seq profile. Likewise, whenCpGmethylationwas quantified
with Illumina’s InfiniumMethylation Assay (Bibikova et al., 2009),
no difference in DNA methylation was detected between cells
treated with control or CK2a RNAi (Figure S4).
Next, we performed MethylCap-seq experiments performed
on control and CK2a-depleted cells to assess the methylation
of repetitive DNA. For this, we used a set of prototypic repeat se-
quences to identify differentially methylated repetitive elements
(see Experimental Procedures for details). This was of particular
interest, as genome-wide studies on DNA methylation in repeti-
tive regions are scarce to date. In many repetitive elements,
we found significant differences in DNA methylation betweenCell Reports 8, 743–75CK2a-knockdown and control cells. As
shown in Figures 4B–4D (see also Figures
S5A and S5B for a detailed view of
the affected repeats), we observed both
significant hypermethylation (elements
in red in Figures 4B and 4C) and signifi-cant hypomethylation (elements in green). Note that dot size re-
flects the element’s statistical significance and dot color indi-
cates the repeat type (e.g., short interspersed nuclear element
[SINE], long interspersed nuclear element [LINE]) of the element
(see also Experimental Procedures). We then investigated how
specific types of differentially methylated elements contribute
to the overall differential methylation pattern (Figure 4C and
4D). As compared to control cells, CK2-knockdown cells mainly
showed hypermethylated elements, mostly of the SINE type
(e. g. Alu), but hypomethylated elements were also identified,
most of them being LINE, long terminal repeat (LTR), or satellite
elements (Figures 4D and S5C). Lastly, using theMethylCap-seq
data, we investigated repeat class location, with a focus on
methylation changes in LINEs and SINEs according to their
genomic location. We found SINEs and LINEs displaying differ-
ential methylation to be located both in intergenic regions and
within gene bodies (Figure S5C).3, August 7, 2014 ª2014 The Authors 747
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Figure 4. Genome-wide CpG Methylation
Analysis
(A) Depletion of cellular CK2a does not affect CpG
methylation of unique sequences. GST-MBD pull-
down (MethylCap) followed by deep sequencing
was performed in control and CK2a-knockdown
cells to assess the effect of CK2a knockdown on
global DNAmethylation pattern. Sequenced reads
were uniquely mapped to the human genome and
peaks were called (see Experimental Procedures
for details). The pairwise scatterplot of the number
of tags (mapped reads) for the RNAi CK2a sample
versus the number of tags for the RNAi control
sample for the detected peaks reveals no signifi-
cant differentially methylated region.
(B) Control and CK2a-depleted cells show signifi-
cant differential methylation of certain repeats.
GST-MBD pull-down (MethylCap) followed by
deep sequencing was performed on control and
CK2a-knockdown cells to assess global changes
in DNA methylation. Sequenced reads were map-
ped to a set of prototypic repeats obtained from the
RepBase Update database (see Figure S5B and
Experimental Procedures for details). The pairwise
scatterplot of the number of tags (mapped reads)
for the RNAi CK2a sample versus the number of
tags for the RNAi control sample for the prototypic
sequences shows both hypermethylated repeats
(in red) and hypomethylated repeats (in green) in
knockdown versus control cells.
(C) Most of the hypermethylated elements are of
the SINE repeat type, while the hypomethylated
elements belong to the LINE, LTR, and satellite
types. On the left, the MA plot shows the distri-
bution of hypo- and hypermethylated elements
(log odds ratio of the tag count in the RNAi CK2a sample versus the tag count in the control sample) divided by the average log tag count. The upper part shows
the hypermethylated elements (log odds ratio > 0) in the RNAi CK2a sample, while the lower part shows hypomethylated elements (log odds ratio < 0). Dot size
reflects the statistical significance and the color indicates the repeat type (e. g. SINE, LINE) to which each element belongs. On the right, the pie charts show the
distribution of tags (% of tags) according to the repeat type for both the hyper- and hypomethylated elements (see Experimental Procedures for details).
(D) Differentially methylated repetitive elements show a large proportion of hypermethylation (70% of tags) and a lower proportion of hypomethylation (30% of
tags) in RNAi-CK2a versus RNAi control cells (upper part, bar plots). For both hyper- and hypomethylated elements, the distribution of tags (% of tags) cor-
responding to each type of repetitive element are shown as a stacked bar plot (see Experimental Procedures for details). Hypermethylated elements are mostly
represented by SINE elements and hypomethylated elements by LINEs, LTRs, and satellites. Hyper- and hypomethylation were assessed by means of Fisher’s
exact statistical test with multiple correction based on Storey’s q value. Elements with a q value < 0.05 and an absolute odds ratio > 1.1 were considered
differentially methylated (see Experimental Procedures for details of analyses).Regulation of Alu SINEs DNA Methylation Is Linked to
CK2-Mediated Dnmt3a Phosphorylation
Next, to zoom in on SINEs, we performed bisulfite sequencing on
Alu elements. We focused on these elements because they dis-
played the biggest changes in methylation upon CK2 knock-
down (cf. Figure 4D). First, we used CK2a-depleted U2OS cells
(i.e. e., the same cells as for the methylated DNA-capture exper-
iments). As shown in Figure 5A, we observed increased methyl-
ation at these repeats after CK2 knockdown, thus confirming our
MethylCap-seq data. Next, we used cells overexpressing CK2
and observed reduced Alu methylation (Figure 5B).
Lastly, we assessed whether the regulation of DNA methyl-
ation by CK2 might be directly attributable to Dnmt3a phosphor-
ylation. For this, we transfected human embryonic kidney
293T (HEK293T) cells with expression constructs encoding
either Dnmt3a WT, a Dnmt3a variant with mutated phosphor-
ylation sites (S386A+S389A), or a phosphomimetic mutant
(S386E+S389E). This was followed by bisulfite sequencing of748 Cell Reports 8, 743–753, August 7, 2014 ª2014 The AuthorsAlu/SINE repeats. As shown in Figure 5C, cells expressing the
nonphosphorylatable double-A Dnmt3a variant (S386A/S389A)
showed increased methylation at Alu repeats as compared to
untransfected cells. In contrast, cells transfected with the phos-
phomimetic double-Emutant (S386E/S8389E) showed the same
degree of methylation at Alu repeats as untransfected cells.
Thus, the above methylation data with Alu SINE elements very
well agree with our findings of methylation changes at the global
level. In addition, when taken together, these data indicate that
CK2-mediated regulation of DNA methylation is directly linked
to Dnmt3a phosphorylation by CK2, although CK2 has many
protein targets in the cell (Allende and Allende, 1995).
CK2-Mediated Phosphorylation of Dnmt3a Favors Its
Heterochromatin Localization
Previous immunofluorescence studies on mouse NIH 3T3
cells have shown that Dnmt3a localizes essentially to hetero-
chromatin, this localization being dependent on a Dnmt3a region
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Figure 5. CK2-Mediated Dnmt3a Phosphorylation Controls Alu/
SINE DNA Methylation
(A) Bisulfite sequencing shows increasedmethylation at Alu/SINE repeats after
CK2 knockdown in U2OS cells. Genomic DNA from cells expressing a controlencompassing the extended PWWP portion (Chen et al., 2004;
Dhayalan et al., 2010; Ge et al., 2004). We thus wondered
whether CK2-mediated phosphorylation of Dnmt3a at S386
and S389 next to its PWWP domain (cf. Figures 1 and 2) might
modulate its localization to heterochromatin.When NIH 3T3 cells
expressing enhanced yellow fluorescent protein (EYFP)-fused
Dnmt3a WT were examined by fluorescence microscopy, we
detected Dnmt3a WT in large spots corresponding to DAPI-
stained heterochromatin as reported earlier (Chen et al., 2004;
Dhayalan et al., 2010; Ge et al., 2004) (Figures 6A and S6F). A
similar heterochromatic localization was observed with the
phosphomimetic double-E Dnmt3a mutant (S386E/S8389E)
(Figures 6A, S6B, and S6F). In contrast, the double-A Dnmt3a
mutant (S386A/S389A) showed a diffuse nuclear staining pattern
excluding heterochromatin and compatible with a spread into
euchromatin (Figures 6A and S6A). To further relate these
observations to CK2-mediated phosphorylation of Dnmt3a, we
performed immunofluorescence experiments as before, this
time in the presence or absence of the CK2 inhibitor 4,5,6,7-tet-
rabromobenzotriazole (TBB). When applied to cells expressing
Dnmt3aWT, TBB treatment led to a partial loss of its heterochro-
matic spot localization in over 60% of the cells, but when the
treatment was applied to cells expressing the S386E/S389E
mutant protein, the subnuclear localization remained unchanged
(Figures 6B and S6C–S6E and data not shown).
To see if mutating the conserved phosphorylation sites
might alter the localization of Dnmt3a in human cells also, we
repeated in human cells our immunofluorescence experiment
(cf. Figure 6). In agreement with the mouse data, we found
that phosphorylation of Dnmt3a by CK2 controls subnuclear
partitioning of Dnmt3a from the heterochromatic to the euchro-
matic portion of the nucleus (Figure S7), as indicated by a transi-
tion from a granular localization pattern for wild-type Dnmt3a
and the phosphomimetic mutant (S386E+S389E) to homoge-
neous subnuclear staining of the nonphosphorylatable mutant
(S386A+S389A).
Together, these data strongly suggest that phosphorylation of
Dnmt3a by CK2 controls the subnuclear distribution of Dnmt3a
between the heterochromatic and the euchromatic compart-
ments of the genome.
DISCUSSION
The origin of DNA methylation patterns is a longstanding mys-
tery, and how de novo DNAmethyltransferases are preferentiallyRNAi or CK2a RNAi were essayed for DNA methylation of Alu repeats after
bisulfite conversion.
(B) Reduction of DNA methylation at Alu/SINE repeats in CK2-overexpressing
cells. DNA was isolated from U2OS cells after CK2 overexpression and from
control cells and the level of Alu/SINE repeat DNA methylation was measured
after bisulfite conversion.
(C) Impact of Dnmt3a phospho mutants on the methylation of Alu/SINE
repeats. Cells were transfected with a construct encoding Dnmt3a WT, a
Dnmt3a mutant lacking phosphorylation sites (S386A+S389A), or a phos-
phomimetic mutant (S386E+S389E). Bisulfite sequencing was then performed
to evaluate methylation at Alu/SINEs. All Alu DNA methylation levels are
reported relative tomethylation observed in the presence of the control RNAi in
the corresponding experiments.
Cell Reports 8, 743–753, August 7, 2014 ª2014 The Authors 749
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Figure 6. CK2-Mediated Phosphorylation of Dnmt3a Favors Its
Heterochromatin Localization
(A) The phosphomimetic double-E Dnmt3a mutant localizes to heterochro-
matin, whereas the double-A Dnmt3a mutant shows spreading into the
euchromatin. Dnmt3a protein localization was determined by fluorescence
microscopy in NIH 3T3 cells transiently expressing the indicated Dnmt3a–
EYFP. Dnmt3a WT was detected as previously reported (Chen et al., 2004;
Dhayalan et al., 2010) in large spots corresponding to heterochromatin.
(B) Inhibition of CK2 by TBB results in partial loss of the heterochromatic
localization of Dnmt3a WT. Immunofluorescence experiments similar to those
depicted in (A) were performed in the presence or absence of the CK2 inhibitor
TBB. In contrast to its effect on Dnmt3a WT, TBB did not affect the localization
of the S386E/S389E mutant protein. The localization experiments were done
three times. The image shows examples of individual cells.targeted to specific regions of the genome is still poorly under-
stood. Here, we provide evidence that DNAmethylation patterns
are regulated by phosphorylation of the Dnmt3a de novo DNA
methyltransferase. Notably, we reveal amechanism for the regu-
lation of DNA methylation at repetitive elements.
Several chromatin-based mechanisms have been proposed
to explain how DNA methyltransferases might find their targets
in the genome (Denis et al., 2011). Our discovery that CK2-medi-
ated Dnmt3a phosphorylation affects CpG methylation may
relate to these mechanisms. The two key residues identified as
important for Dnmt3a enzymatic activity and localization, S386
and S389, are situated within a region encompassing the
PWWP domain, known to be involved in targeting Dnmt3a to
heterochromatic sequences (Chen et al., 2004; Dhayalan et al.,750 Cell Reports 8, 743–753, August 7, 2014 ª2014 The Authors2010; Ge et al., 2004). This suggests an interesting possibility:
that phosphorylation of the extended PWWP domain might
modulate the ability of Dnmt3a to interact with one or more com-
ponents of the histone-modification and chromatin-remodeling
systems (e.g., the SUV39H H3K9 enzymes [Lehnertz et al.,
2003] or LSH [Huang et al., 2004]), involved in establishing
DNA methylation at heterochromatin.
While our analyses of global methylation by HPCE point to
a CK2-mediated decrease in methylation, genome-wide map-
ping of DNA methylation (by MethylCap-Seq) indicates a more
complicated response. CK2 knockdown led to a methylation in-
crease affecting 70% of the differentially methylated tags, mainly
at SINE elements. In addition, a decrease in methylation was
observedatasmallernumberof sites (e.g., atLINEsandsatellites).
These data are consistent, because SINE elements contain more
than one-third of the total CpGs (more than any other repeats) and
account for more than one-quarter of the total CpG methylation
(again well above other repeats) (e.g., (Cordaux and Batzer,
2009; Lander, 2011; Rollins et al., 2006). Furthermore, our Methyl-
Cap-seq data show that a greater number of SINE elements than
LINE/LTR/satellite repeats display changes in methylation after
CK2 knockdown (Figures 4C and 4D). All in all, these observations
strongly suggest that the CK2-mediated reduction in global DNA
methylation (as seen by HPCE; Figures 3D and 3E) results mainly
from the decrease in methylation of the overrepresented SINE
CpGs (as seen by MethylCap-seq; Figures 4B–4D).
Our findings suggesting that CK2-mediated phosphorylation
plays an important role both in guiding Dnmt3a to specific
portions of the genome and in controlling DNA methylation at
certain repeats may shed light on the compartmentalization of
DNA methylation in the genome. We show that phosphorylation
of Dnmt3a not only reduces its activity but also reinforces its
binding to heterochromatin. Both of these effects reduce its
action on euchromatic targets, as exemplified by the observed
hypermethylation at SINEs. Interestingly, this dual mode of
regulation has recently been reported for Dnmt3L as well. Since
Dnmt3L increases the activity and euchromatic localization of
Dnmt3a, it is reasonable to think that this action may counteract
the control of Dnmt3a by CK2. Thus, the combined regulation of
activity and localization seems to be a general phenomenon, at
least for Dnmt3a. On the basis of our data, we propose that
the pool of Dnmt3a available for euchromatin-associated pro-
cesses is kept low by CK2-mediated phosphorylation, which tar-
gets the enzyme to the heterochromatin and reduces its activity
(see Figure 7 for a summary of our data).
Is the regulation of DNA methylation by CK2-mediated phos-
phorylation of Dnmt3a conserved between mice and humans?
Three facts suggest that it is: (1) both mouse and human Dnmt3a
are observed to be phosphorylated by CK2; (2) the region sur-
rounding the Dnmt3a phosphorylation sites displays very strong
conservation between mice and humans; and (3) phosphoryla-
tion of Dnmt3a by CK2 controls the subnuclear partitioning of
Dnmt3a in both mouse and human cells.
Lastly, our results might also have important consequences
for human disease. The constitutively active CK2 kinase is tightly
regulated in normal cells. Previous studies have evidenced
increased CK2 expression in cancers (Trembley et al., 2009) as
well as decreased Alu SINE methylation (Bae et al., 2012; Xie
Figure 7. Summary of Results
Left: In CK2-overexpressing cells or in the
phosphomimetic Dnmt3a mutant, lower Alu/SINE
methylation is observed and Dnmt3a is found
essentially located in the heterochromatin. Right:
Conversely, in cells with downregulated CK2
or harboring the nonphosphorylatable Dnmt3a
mutant, higher Alu/SINE methylation is detected
and Dnmt3a is more localized to the euchromatin.et al., 2010). The molecular basis of these observations remains
largely unknown. Our bisulfite sequencing data reveal that Alu
repeats show decreased methylation upon CK2 overexpression
and in the phosphomimetic Dnmt3a mutant (S386E+S389E).
While speculative at this stage, it is conceivable that higher
CK2 levels, by leading to increased Dnmt3a phosphorylation,
might be related to the reported reduced methylation of some
Alu repeats in cancers. Future work will be needed to address
this exciting possibility. Further studiesmay also beworth pursu-
ing to assess whether CK2-mediated regulation of CpG methyl-
ation is operational also at non-CG methylation sites. Since
previous reports show that non-CG methylation exists essen-
tially in embryonic stem cells and the brain (Lister et al., 2009),
it will be interesting to study the effect of CK2 on non-CpG
methylation in these cells in subsequent studies.
In conclusion, our findings shed light on how posttranslational
modifications might fine-tune the function of de novo DNAmeth-
yltransferases. They reveal an important mode of regulation that
contributes to shaping the CpG methylation ground within the
genome.EXPERIMENTAL PROCEDURES
Cell Culture and Transfections
U2OS and NIH 3T3 cells were maintained in Dulbecco’s modified Eagle’s
medium (GIBCO BRL) supplemented with 10% fetal bovine serum and
grown at 37C under 5% CO2. Inducible CK2 Tet-Off U2OS cells were main-
tained as already described (Vilk et al., 1999, 2001). U2OS cells (HTB-96)
were purchased from the ATCC and NIH 3T3 cells (ACC-59) from the
German DSZM. All cells were regularly tested for mycoplasma contamination.
Transient transfections were performed as described previously (Deplus
et al., 2013). The vectors pcDNA3.1-myc-Dnmt3a and pcDNA3.1-EYFP-
Dnmt3a have been described (Dhayalan et al., 2010; Vire´ et al., 2006).
The vectors pcDNA3.1-EYFP-Dnmt3a-S386E/S389E and pcDNA3.1-EYFP-
Dnmt3a-S386A/S389A were derived from pcDNA3.1-EYFP-Dnmt3a by muta-
genesis. The presence of each desired mutation was checked by sequencing.
In Vivo Labeling with [32P]Orthophosphate
U2OS cells were washed and incubated in 4 ml phosphate-free medium
containing 1.2 mCi of [32P] orthophosphate (Amersham) for 4 hr at 37C with
5% CO2. In experiments involving labeling of Myc-Dnmt3a proteins, polyethy-
lenimine (Euromedex) was used to transfect cells with expression plasmids.
The cells were then washed three times with PBS and lysed in IPH buffer
(Vire´ et al., 2006). For immunoprecipitation, Myc (2 mg, sc 42, Santa Cruz) or
human-Dnmt3a antibody (2 mg, IMG 268, Imgenex) was used. Immunocom-
plexes were collected, washed four times with PBS, and then resolved by
SDS-PAGE (6% polyacrylamide) prior to autoradiography.Cell Reports 8, 743–75Kinase Assays
Immunoprecipitated material from transfected
U2OS cells expressing Myc-Dnmt3a were incu-
bated for 30 min at 30C in kinase buffer with
2.5 mCi of [g-32P]-ATP or [g-32P]-GTP (Amersham). The beads were washed
four times with kinase buffer and the proteins bound to them were released
and resolved by SDS-PAGE (6% acrylamide) followed by autoradiography.
Apigenin (40 mM, Sigma-Aldrich) and Emodin (40 mM, Sigma) were used
as CK2 kinase inhibitors, and H89 (100 mM, Sigma) and staurosporine
(1 mM, Sigma) were used as PKA and PKC inhibitors, respectively. In vitro
kinase assays with recombinant CK2 or various Dnmt3a fragments were
performed as described previously (Williams et al., 2009). Plasmid pET28a-
Dnmt3a2 and the catalytic domain of pET28a-Dnmt3a have been described
(Gowher and Jeltsch, 2002). Plasmids pET28a-Dnmt3a2-S386E, pET28a-
Dnmt3a2-S389E, pET28a-Dnmt3a2-S386E/S389E, and pET28a-Dnmt3a2-
S386A/S389A were derived from pET28a-Dnmt3a2 by mutagenesis.
pGEX6P2 3a PWWP-S386A, pGEX6P2 3a PWWP-S389A, and pGEX6P2
3aPWWP-S386A/S389A were derived from pGEX6P2 3a-PWWP by site-
directed mutagenesis (Dhayalan et al., 2010). The pGEX6P2 3a ADD domain
constructs were prepared by cloning of the PCR product amplified from the
Dnmt3a full-length construct (Zhang et al., 2010). All constructs were checked
by DNA sequencing.
Mass Spectrometry
The extended PWWP domain (residues 279–420) was phosphorylated by
recombinant CK2 as described above and digested with chymotrypsin. The
resulting peptides were analyzed by MALDI mass spectroscopy with the
help of an Autospot II device (Bruker Daltonics), as previously described
(Bonk et al., 2002). At a sequence coverage of 72.4% and an intensity
coverage of 38.2%, we observed one peptide (2052.96 Da) corresponding
to a doubly phosphorylated fragment (FPACHDSDESDSGKAVEV, theoretical
mass: 2052.73 Da) containing S386 and S389. This peak was not detected in
the absence of phosphorylation and it does not correspond to any theoretical
unmodified peptide from PWWP.
Antibody Generation and Western Blotting
Antibody against S390/S393-phosphorylated human Dnmt3a was raised with
a keyhole limpet hemocyanin (KLH)-conjugated doubly phosphorylated pep-
tide. The phosphopeptide-KLH conjugates were used to immunize rabbits ac-
cording to standard protocols. This antibody is commercialized by Abcam
(ab87763). For western blotting, U2OS cells were resuspended in SDS-PAGE
buffer, sonicated, and incubatedat 70C for 15min. The suspensionwascentri-
fuged, and the equivalent of 13 105 cells was fractionated bySDS-PAGE. After
transfer, the nitrocellulose membrane was probed and reprobed with the
indicated antibodies according to standard protocols. Antibodies against
CK2a (polyclonal antiserum directed against the C-terminal synthetic peptide
a-[376–391]) have been described (Vilk et al., 2001). Antibodies against Myc
(Santa Cruz, sc42) and b-actin (Abcam, ab8226) were used for immunoprecip-
itation or western blotting as indicated in the figure legends.
DNA Methyltransferase Assays
His-Dnmt3a was expressed and purified and DNA methylation experiments
were conducted as described previously (Jurkowska et al., 2008). Alterna-
tively, transfected-cell extracts were used for DNA methyltransferase assays
carried out as previously described (Brenner et al., 2005; Vire´ et al., 2006).3, August 7, 2014 ª2014 The Authors 751
The transfecting plasmids have been described (Fuks et al., 2000; Penner
et al., 1997). Error bars represent SD of duplicates.
Quantification of Global 5mC
Quantification of 5mCby HPCEwas performed as previously described (Fraga
et al., 2005). Error bars represent SD of at least two replicates. In Figure 3D, we
used two inducible Tet-Off U2OS cell lines, one stably transfected with a
construct encoding CK2aWT and the other with a construct encoding a cata-
lytically inactive mutant (Vilk et al., 1999). The observed difference between the
two low-CK2a controls (lane 1 versus 3) is likely due to the known impact of cell
culture passages on DNA methylation levels (e.g., Shmookler Reis and Gold-
stein, 1982), the number of passages having been different for the two lines.
RNAi, Retroviral Infection, and RT-PCR Analysis
Interfering RNAs targeting CK2a were generated as previously described
(Deplus et al., 2013). Briefly, the target sequence used to silence CK2a was
inserted as a short hairpin into the pRetroSuper (pRS) retroviral vector accord-
ing to the manufacturer’s recommendations (OligoEngine) to form RNAi CK2a.
Retrovirus production by HEK293 gag-pol cells and infection of target
cells were performed as described elsewhere (Vire´ et al., 2006). Infected cells
were selected with 1 mg/ml puromycin (Sigma). RNA purification and RT-PCR
analysis were performed as described previously (Vire´ et al., 2006). Primer se-
quences are listed in Table S1.
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